Morgan Stanley set a $100.00 target price on Zoetis (NYSE:ZTS) in a research report report published on Friday morning. The firm currently has a hold rating on the stock.
ZTS has been the subject of several other reports. Stifel Nicolaus boosted their target price on Zoetis from $86.00 to $95.00 and gave the stock a buy rating in a report on Friday, August 3rd. Cantor Fitzgerald set a $98.00 target price on Zoetis and gave the stock a buy rating in a report on Friday, July 27th. Jefferies Financial Group set a $96.00 target price on Zoetis and gave the stock a buy rating in a report on Friday, July 13th. Zacks Investment Research lowered Zoetis from a buy rating to a hold rating in a report on Friday, October 5th. Finally, Bank of America boosted their target price on Zoetis from $97.00 to $100.00 and gave the stock a buy rating in a report on Monday, July 30th. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $93.19.
ZTS traded down $1.48 on Friday, hitting $92.77. The company had a trading volume of 2,685,303 shares, compared to its average volume of 2,452,234. Zoetis has a 1-year low of $67.44 and a 1-year high of $96.57. The company has a debt-to-equity ratio of 2.50, a quick ratio of 2.92 and a current ratio of 4.38. The firm has a market cap of $44.70 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 1.78 and a beta of 0.97.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 1st. The company reported $0.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.06. Zoetis had a return on equity of 77.52% and a net margin of 20.35%. The firm had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same period in the previous year, the company earned $0.65 EPS. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. As a group, analysts anticipate that Zoetis will post 3.1 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be given a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.54%. The ex-dividend date is Monday, November 19th. Zoetis’s dividend payout ratio is currently 20.83%.
In other Zoetis news, insider Roman Trawicki sold 8,266 shares of Zoetis stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of $92.53, for a total value of $764,852.98. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Catherine A. Knupp sold 46,816 shares of Zoetis stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $90.84, for a total value of $4,252,765.44. Following the completion of the transaction, the insider now directly owns 81,640 shares in the company, valued at $7,416,177.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 208,467 shares of company stock worth $19,071,625. Company insiders own 0.35% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ZTS. Valeo Financial Advisors LLC increased its position in shares of Zoetis by 34.4% during the second quarter. Valeo Financial Advisors LLC now owns 2,210 shares of the company’s stock valued at $202,000 after purchasing an additional 566 shares during the period. Dupont Capital Management Corp increased its position in shares of Zoetis by 2.5% during the second quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock valued at $2,088,000 after purchasing an additional 601 shares during the period. Dorsey Wright & Associates increased its position in shares of Zoetis by 7.9% during the second quarter. Dorsey Wright & Associates now owns 8,386 shares of the company’s stock valued at $714,000 after purchasing an additional 617 shares during the period. Rehmann Capital Advisory Group increased its position in shares of Zoetis by 40.5% during the second quarter. Rehmann Capital Advisory Group now owns 2,190 shares of the company’s stock valued at $187,000 after purchasing an additional 631 shares during the period. Finally, Wrapmanager Inc. increased its position in shares of Zoetis by 7.9% during the second quarter. Wrapmanager Inc. now owns 9,176 shares of the company’s stock valued at $782,000 after purchasing an additional 672 shares during the period. 89.75% of the stock is currently owned by institutional investors.
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Further Reading: Cost of Debt
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.